Ultragenyx Pharma Files For $86.25 Mln IPO

(RTTNews) - Ultragenyx Pharmaceutical Inc, a rare disease drug developer, filed on Friday with the U.S. Securities and Exchange Commission for an initial public offering of up to $86.25 million. The company did not specify the number of shares to be sold and the price range for the proposed offering.

The Novato, California -based company plans to list on the NASDAQ under the symbol "RARE".

J.P. Morgan Securities LLC and Morgan Stanley & Co. LLC are acting as joint book-running managers of the offering

Ultragenyx Pharmaceutical, which was founded in 2010, is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.